YIELD10 BIOSCIENCE, INC.: Nasdaq/NYSE listing notice — Yield10 Bioscience receives Nasdaq deficiency notice; plans reverse stock split

YIELD10 BIOSCIENCE, INC.

Nasdaq staff notified Yield10 on March 26, 2024 it is ineligible for a second 180-day bid price compliance period due to insufficient stockholders' equity.
Company does not meet the $5 million minimum stockholders' equity initial listing requirement for The Nasdaq Capital Market.
Yield10 must present its views to the Nasdaq Panel by April 2, 2024 and plans a special shareholder meeting on April 26, 2024 to approve a reverse stock split.
Stock continues trading on The Nasdaq Capital Market under symbol YTEN; no immediate delisting effect but compliance is uncertain.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity

Exact text from the filing

March 26, 2024, the Company received written notice (the “Notice”) from the Staff stating that the Company is not eligible for a second 180 day compliance period for the Minimum Bid Price Rule deficiency because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The Notice indicates that the Company must present its views with respect to this deficiency to the Panel in writing no later than April 2, 2024, which it intends to do. Among other measures, the Company intends to schedule a special meeting of its sha

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-041138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.